About Owkin
Owkin is a Technology company based in Paris (France) founded in 2016 by Gilles Wainrib and Thomas Clozel. An agentic AI platform is developed for biomedical research insights. It operates on a AI-as-a-Service, Professional Services, and HealthTech model in Technology and Healthcare sectors. Owkin has raised $321.1 million across 13 funding rounds from investors including Sanofi, Mubadala and Plug and Play Tech Center. The company has 396 employees. Owkin was last valued at $1 billion in November 2021. Its chief executive, as recorded, is Thomas Clozel. Its website owkin.com draws about 43 thousand monthly visits. Owkin offers products and services including Owkin K Pro, Owkin K Navigator, MSIntuit® CRC, and RlapsRisk® BC. Its focus areas include Artificial Intelligence, Healthcare AI, Biotechnology and Drug Discovery. Its legal entity is Owkin, Inc.
Company details
Owkin is engaged in transforming healthcare by leveraging agentic AI to understand complex biology. The company is involved in drug discovery, development, and diagnostics within the biopharma and healthcare sectors. Solutions are developed to process vast biological data, uncover hidden relationships, and generate actionable insights. Multimodal patient data is accessed from diverse populations through partnerships with top academic institutions. Owkin K, an AI platform, is utilized to drive decision-making and accelerate breakthroughs across various teams. Additionally, diagnostic tools are provided for precision pathology in oncology, supporting clinical trials and routine clinical use.
- Annual Revenue$12.18 M (USD)as on Dec 31, 2020
- Net Profit$1.83 M (USD)as on Dec 31, 2020
- EBITDA-$217.07 K (USD)as on Dec 31, 2020
- Total Equity Funding$321.1M (USD)
in 13 rounds
- Latest Funding Round$33M (USD), Series B
Mar 2026
- InvestorsSanofi
& 21 more
- Employee Count396
Products & Services of Owkin
Owkin offers a comprehensive portfolio of products and services, including Owkin K Pro, Owkin K Navigator, MSIntuit® CRC, and RlapsRisk® BC.
Agentic AI tool for biopharma decision-making support.
AI co-pilot for biomedical research and exploration.
AI tool for optimizing colorectal cancer MSI testing.
AI assesses relapse risk in early breast cancer.
Apps and channels of Owkin
its YouTube channel Owkin has 565 subscribers and 30 videos.
Videos from Owkin
The most watched videos on Owkin's YouTube channel, Owkin (565 subscribers). Click a video to play it here.
More on Owkin.
Funding Insights of Owkin
Owkin has successfully raised a total of $321.1M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $33 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $321.1M
- Total Rounds 13
- Last Round Series B — $33M
- First Round $2.1M
(Nov 2016)
- Investors Count 22
Latest 10 of 13 funding rounds of Owkin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $33M | Series B | – | OTB Ventures, AIC | – |
| Jan 2023 | $216,355 | Grant | – | – | |
| Jun 2022 | $80M | Series B | – | – | |
| Nov 2021 | $180M | Series B | $1B | – | |
| Mar 2021 | $568,238 | Grant | – | – | |
| Jun 2020 | $18M | Series A | – | – | |
| May 2020 | $25M | Series A | – | MACSF, Bpifrance | |
| Mar 2019 | Series A | – | F-Prime Capital, Eight Roads Ventures | ||
| May 2018 | $5M | Series A | – | Google Ventures | – |
| May 2018 | $270,859 | Grant | – | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Nov 2021 | $1B | •••••••• |
Last known valuation $1B (Nov 2021). 22 investors in total: 18 institutional and 4 angel.
Investors in Owkin
Owkin has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Sanofi, Mubadala and Plug and Play Tech Center.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in technology startups through a global ecosystem. | cathayinnovation.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Venture capital investments are directed toward multiple sectors. | njfcapital.com | London, United Kingdom | ||
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Early-stage startups across France are invested in by Frst Capital. | frst.vc | Paris, France | ||
Startups are accelerated and invested in across multiple tech sectors. | 2006 | plugandplaytechcenter.com | Sunnyvale, United States | |
Venture capital fund focused on multiple sectors | otiumcapital.com | Paris, France | ||
| otb.vc | ||||
| aicapital.ai |
Investor details for Owkin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Owkin
142 people are tracked at Owkin (58 in leadership, 17 in board & advisors, 67 in team); the tracked headcount is 396.
| Name | Role | Group |
|---|---|---|
Gilles Wainrib | Co-Founder | Leadership |
Thomas Clozel | Co-Founder & CEO | Leadership |
Leo Cunningham | Chief Information Security Officer | Leadership |
John Klein | Head Of Frontier Research - Lead Research Scientist | Leadership |
Meriem Sefta | Chief Diagnostics Officer | Leadership |
Ablan De La Sablière | Chief Operating Officer | Leadership |
Anna Huyghues-Despointes | Interim Chief Financial Officer | Leadership |
Sandrine Sanchez | Lab Director | Leadership |
Hiroshi Yamazaki | Senior Director, Business Development | Leadership |
Caroline Hoffmann | Head Of Oncology | Leadership |
Amelie Ravasé | Head of People Ops & Partners | Leadership |
Gwendolyn Courtois | Early Adoption And Sales Strategy Director - Diagnostics | Leadership |
Yedidia Levy-Zauberman | SVP, Head of Public Affairs & Impact | Leadership |
Rodrigo Barnes | Chief Technology Officer | Leadership |
Anne-Charlotte Paut | Svp, Head Of Legal | Leadership |
Greg Taylor | VP Global Commercial Diagnostics | Leadership |
Darius Meadon | Chief Marketing Officer | Leadership |
Hubert Chaperon | Chief Growth Officer | Leadership |
Mariabrisa Olivares | Chief People Officer | Leadership |
Elodie Vigne | HR Ops R&tech & Marketing HR Partner | Leadership |
122 more people are available in the full profile.
Complete people profiles for Owkin
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Owkin
4 dated milestones of Owkin across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Owkin is founded.
- Funding First funding round of $2.1M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series B, of $33.0M.
Web traffic of Owkin
The website of Owkin (owkin.com) receives about 42.6K visits a month and ranks #724,166 among all websites worldwide, #5,796 in Business Services.
- Monthly visits42.6K
▼ 10.7% vs previous month
- Unique visitors19.4K
per month
- Global rank#724,166
among all websites
- Category rank#5,796
Business and Consumer Services · Business Services
- Bounce rate45%
- Pages per visit1.8
- Average visit1 min 37 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Owkin. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bioptimus.com | 100% | 12.6K | #1,902,954 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Owkin
Complete news archive for Owkin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Owkin
Owkin was founded in 2016.
Owkin is headquartered in Paris, France. It is registered at Paris, Ile de France, France.
Thomas Clozel is the CEO of Owkin, as recorded in our data. They have also founded this company.
Owkin is a funded company, having raised a total of $321.1M across 13 funding rounds to date. The company's 1st funding round was a Grant of $270.86K, raised on Nov 2016.
Owkin has 396 employees.
Annual revenue of Owkin is $12.18M as on Dec 31, 2020.
Owkin is engaged in transforming healthcare by leveraging agentic AI to understand complex biology. The company is involved in drug discovery, development, and diagnostics within the biopharma and healthcare sectors. Solutions are developed to process vast biological data, uncover hidden relationships, and generate actionable insights. Multimodal patient data is accessed from diverse populations through partnerships with top academic institutions. Owkin K, an AI platform, is utilized to drive decision-making and accelerate breakthroughs across various teams. Additionally, diagnostic tools are provided for precision pathology in oncology, supporting clinical trials and routine clinical use.
Owkin offers Owkin K Pro, Owkin K Navigator, MSIntuit® CRC, and RlapsRisk® BC.
Owkin has 22 investors. Key investors include Sanofi, Mubadala, Plug and Play Tech Center, Bpifrance, and European Union.
The valuation of Owkin is $1B as of Nov 2021.
Owkin operates through Owkin, Inc.